Having raised $27 million in a Series B financing round, Exosome Diagnostics said this week that it plans to use the funds to support the development and commercialization of a number of non-invasive fluid-based molecular diagnostic products based on its proprietary platform technology for capturing and processing nucleic acids from microvesicles.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.